BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020;80:1267-1292. [PMID: 32696108 DOI: 10.1007/s40265-020-01367-z] [Cited by in Crossref: 81] [Cited by in F6Publishing: 72] [Article Influence: 40.5] [Reference Citation Analysis]
Number Citing Articles
1 Christie MJ, Irving AT, Forster SC, Marsland BJ, Hansbro PM, Hertzog PJ, Nold-Petry CA, Nold MF. Of bats and men: Immunomodulatory treatment options for COVID-19 guided by the immunopathology of SARS-CoV-2 infection. Sci Immunol 2021;6:eabd0205. [PMID: 34533977 DOI: 10.1126/sciimmunol.abd0205] [Reference Citation Analysis]
2 Rizk JG, Gupta A, Lazo JG Jr, Sardar P, Henry BM, Lavie CJ, Effron MB. To Anticoagulate or Not to Anticoagulate in COVID-19: Lessons after 2 Years. Semin Thromb Hemost 2022. [PMID: 35468641 DOI: 10.1055/s-0042-1744302] [Reference Citation Analysis]
3 Zheng W, Sun HL, Cai H, Zhang Q, Ng CH, Xiang YT. Antidepressants for COVID-19: A systematic review. J Affect Disord 2022;307:108-14. [PMID: 35339571 DOI: 10.1016/j.jad.2022.03.059] [Reference Citation Analysis]
4 Rabaan AA, Al-Ahmed SH, Muhammad J, Khan A, Sule AA, Tirupathi R, Mutair AA, Alhumaid S, Al-Omari A, Dhawan M, Tiwari R, Sharun K, Mohapatra RK, Mitra S, Bilal M, Alyami SA, Emran TB, Moni MA, Dhama K. Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Immunopathology and Immunomodulatory Drugs to Counter Cytokine Storm. Vaccines (Basel) 2021;9:436. [PMID: 33946736 DOI: 10.3390/vaccines9050436] [Cited by in Crossref: 4] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
5 El-Zein RS, Cardinali S, Murphy C, Keeling T. COVID-19-associated meningoencephalitis treated with intravenous immunoglobulin. BMJ Case Rep 2020;13:e237364. [PMID: 32895254 DOI: 10.1136/bcr-2020-237364] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
6 . Acknowledgement to Referees. Drugs 2020;80:1875-9. [DOI: 10.1007/s40265-020-01442-5] [Reference Citation Analysis]
7 Kasozi KI, Niedbała G, Alqarni M, Zirintunda G, Ssempijja F, Musinguzi SP, Usman IM, Matama K, Hetta HF, Mbiydzenyuy NE, Batiha GE, Beshbishy AM, Welburn SC. Bee Venom-A Potential Complementary Medicine Candidate for SARS-CoV-2 Infections. Front Public Health 2020;8:594458. [PMID: 33363088 DOI: 10.3389/fpubh.2020.594458] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
8 Aggarwal R, Dewan A, Pandey A, Trehan N, Majid MA. Efficacy of high-dose intravenous immunoglobulin in severe and critical COVID-19: A retrospective cohort study. International Immunopharmacology 2022;106:108615. [DOI: 10.1016/j.intimp.2022.108615] [Reference Citation Analysis]
9 Shetty R, Murugeswari P, Chakrabarty K, Jayadev C, Matalia H, Ghosh A, Das D. Stem cell therapy in coronavirus disease 2019: current evidence and future potential. Cytotherapy 2021;23:471-82. [PMID: 33257213 DOI: 10.1016/j.jcyt.2020.11.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Luo Z, Chen W, Xiang M, Wang H, Xiao W, Xu C, Li Y, Min J, Tu Q. The preventive effect of Xuebijing injection against cytokine storm for severe patients with COVID-19: A prospective randomized controlled trial. Eur J Integr Med 2021;42:101305. [PMID: 33552315 DOI: 10.1016/j.eujim.2021.101305] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
11 Zolotovskaia IA, Shatskaia PR, Davydkin IL, Shavlovskaya OA. [Post-COVID-19 asthenic syndrome]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:25-30. [PMID: 34037351 DOI: 10.17116/jnevro202112104125] [Reference Citation Analysis]
12 Chang JC. COVID-19 Sepsis: Pathogenesis and Endothelial Molecular Mechanisms Based on "Two-Path Unifying Theory" of Hemostasis and Endotheliopathy-Associated Vascular Microthrombotic Disease, and Proposed Therapeutic Approach with Antimicrothrombotic Therapy. Vasc Health Risk Manag 2021;17:273-98. [PMID: 34103921 DOI: 10.2147/VHRM.S299357] [Reference Citation Analysis]
13 Barbosa LC, Gonçalves TL, de Araujo LP, Rosario LVO, Ferrer VP. Endothelial cells and SARS-CoV-2: An intimate relationship. Vascul Pharmacol 2021;137:106829. [PMID: 33422689 DOI: 10.1016/j.vph.2021.106829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
14 Marocco R, Carraro A, Zingaropoli MA, Nijhawan P, Tortellini E, Guardiani M, Mengoni F, Zuccalà P, Belvisi V, Kertusha B, Parente A, Del Borgo C, Vullo V, Ciardi M, Mastroianni CM, Lichtner M. Role of Tocilizumab in Down Regulating sCD163 Plasmatic Levels in a Cohort of COVID-19 Patients. Front Immunol 2022;13:871592. [DOI: 10.3389/fimmu.2022.871592] [Reference Citation Analysis]
15 Hall K, Mfone F, Shallcross M, Pathak V. Review of Pharmacotherapy Trialed for Management of the Coronavirus Disease-19. Eurasian J Med 2021;53:137-43. [PMID: 34177298 DOI: 10.5152/eurasianjmed.2021.20384] [Reference Citation Analysis]
16 Vrachatis DA, Papathanasiou KA, Giotaki SG, Raisakis K, Kossyvakis C, Kaoukis A, Kolokathis F, Deftereos G, Iliodromitis KE, Avramides D, Bogossian H, Siasos G, Giannopoulos G, Reimers B, Lansky A, Tardif JC, Deftereos S. Immunologic Dysregulation and Hypercoagulability as a Pathophysiologic Background in COVID-19 Infection and the Immunomodulating Role of Colchicine. J Clin Med 2021;10:5128. [PMID: 34768648 DOI: 10.3390/jcm10215128] [Reference Citation Analysis]
17 Terrier O, Si-Tahar M, Ducatez M, Chevalier C, Pizzorno A, Le Goffic R, Crépin T, Simon G, Naffakh N. Influenza viruses and coronaviruses: Knowns, unknowns, and common research challenges. PLoS Pathog 2021;17:e1010106. [PMID: 34969061 DOI: 10.1371/journal.ppat.1010106] [Reference Citation Analysis]
18 Burkert FR, Lanser L, Bellmann-Weiler R, Weiss G. Coronavirus Disease 2019: Clinics, Treatment, and Prevention. Front Microbiol 2021;12:761887. [PMID: 34858373 DOI: 10.3389/fmicb.2021.761887] [Reference Citation Analysis]
19 Lin Z, Phyu WH, Phyu ZH, Mon TZ. The Role of Steroids in the Management of COVID-19 Infection. Cureus 2021;13:e16841. [PMID: 34522487 DOI: 10.7759/cureus.16841] [Reference Citation Analysis]
20 Yang G, Zhang S, Wang Y, Li L, Li Y, Yuan D, Luo F, Zhao J, Song X, Zhao Y. Aptamer blocking S-TLR4 interaction selectively inhibits SARS-CoV-2 induced inflammation. Sig Transduct Target Ther 2022;7. [DOI: 10.1038/s41392-022-00968-2] [Reference Citation Analysis]
21 Rizk JG, Wenziger C, Tran D, Hashemi L, Moradi H, Streja E, Ahluwalia A. Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19. Drugs 2021. [PMID: 34914085 DOI: 10.1007/s40265-021-01639-2] [Reference Citation Analysis]
22 Yan X, Wang S, Ma P, Yang B, Si D, Liu G, Liu L, Ding M, Yang W, Li J, Sun H, Yang P. Cardiac injury is associated with inflammation in geriatric COVID-19 patients. J Clin Lab Anal 2021;35:e23654. [PMID: 33210392 DOI: 10.1002/jcla.23654] [Reference Citation Analysis]
23 Olszewska-Parasiewicz J, Szarpak Ł, Rogula S, Gąsecka A, Szymańska U, Kwiatkowska M, Jaguszewski MJ, Sierpiński R, Zaczyński A, Wierzba W, Kosior DA. Statins in COVID-19 Therapy. Life (Basel) 2021;11:565. [PMID: 34208435 DOI: 10.3390/life11060565] [Reference Citation Analysis]
24 Nhean S, Varela ME, Nguyen YN, Juarez A, Huynh T, Udeh D, Tseng AL. COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/Imdevimab) and Pharmacological Considerations. J Pharm Pract 2021;:8971900211048139. [PMID: 34597525 DOI: 10.1177/08971900211048139] [Reference Citation Analysis]
25 Verma HK, Bhaskar L. SARS-CoV-2 infection in people with pre-existing liver disease: Further research is warranted. World J Gastroenterol 2021; 27(45): 7855-7858 [PMID: 34963747 DOI: 10.3748/wjg.v27.i45.7855] [Reference Citation Analysis]
26 Ahlström B, Frithiof R, Hultström M, Larsson IM, Strandberg G, Lipcsey M. The swedish covid-19 intensive care cohort: Risk factors of ICU admission and ICU mortality. Acta Anaesthesiol Scand 2021. [PMID: 33438198 DOI: 10.1111/aas.13781] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
27 Rizk JG, Gupta A, Sardar P, Henry BM, Lewin JC, Lippi G, Lavie CJ. Clinical Characteristics and Pharmacological Management of COVID-19 Vaccine-Induced Immune Thrombotic Thrombocytopenia With Cerebral Venous Sinus Thrombosis: A Review. JAMA Cardiol 2021. [PMID: 34374713 DOI: 10.1001/jamacardio.2021.3444] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Nagoor Meeran MF, Javed H, Sharma C, Goyal SN, Kumar S, Jha NK, Ojha S. Can Echinacea be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019. Heliyon 2021;7:e05990. [PMID: 33585706 DOI: 10.1016/j.heliyon.2021.e05990] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
29 Lico C, Santi L, Baschieri S, Noris E, Marusic C, Donini M, Pedrazzini E, Maga G, Franconi R, Di Bonito P, Avesani L. Plant Molecular Farming as a Strategy Against COVID-19 - The Italian Perspective. Front Plant Sci 2020;11:609910. [PMID: 33381140 DOI: 10.3389/fpls.2020.609910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
30 Wei WL, Wu SF, Li HJ, Li ZW, Qu H, Yao CL, Zhang JQ, Li JY, Wu WY, Guo DA. Chemical profiling of Huashi Baidu prescription, an effective anti-COVID-19 TCM formula, by UPLC-Q-TOF/MS. Chin J Nat Med 2021;19:473-80. [PMID: 34092298 DOI: 10.1016/S1875-5364(21)60046-8] [Reference Citation Analysis]
31 Moretto F, Sixt T, Devilliers H, Abdallahoui M, Eberl I, Rogier T, Buisson M, Chavanet P, Duong M, Esteve C, Mahy S, Salmon-Rousseau A, Catherine F, Blot M, Piroth L. Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19? Int J Infect Dis 2021;105:256-60. [PMID: 33508478 DOI: 10.1016/j.ijid.2021.01.051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
32 Das A, Rana S. The role of human C5a as a non-genomic target in corticosteroid therapy for management of severe COVID19. Comput Biol Chem 2021;92:107482. [PMID: 33845430 DOI: 10.1016/j.compbiolchem.2021.107482] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Gopcsa L, Bobek I, Bekő G, Lakatos B, Molnár E, Réti M, Reményi P, Sinkó J, Szlávik J, Tatai G, Vályi-Nagy I. Common points of therapeutic intervention in COVID-19 and in allogeneic hematopoietic stem cell transplantation associated severe cytokine release syndrome. Acta Microbiol Immunol Hung 2021. [PMID: 34797216 DOI: 10.1556/030.2021.01620] [Reference Citation Analysis]
34 Johnson HM, Lewin AS, Ahmed CM. SOCS, Intrinsic Virulence Factors, and Treatment of COVID-19. Front Immunol 2020;11:582102. [PMID: 33193390 DOI: 10.3389/fimmu.2020.582102] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
35 Bhattacharjee A, Saha M, Halder A, Debnath A, Mukherjee O. Therapeutics and Vaccines: Strengthening Our Fight Against the Global Pandemic COVID-19. Curr Microbiol 2021;78:435-48. [PMID: 33392670 DOI: 10.1007/s00284-020-02310-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Zhao L, Liu H, Wang Y, Wang S, Xun D, Wang Y, Cheng Y, Zhang B. Multimodal Identification by Transcriptomics and Multiscale Bioassays of Active Components in Xuanfeibaidu Formula to Suppress Macrophage-Mediated Immune Response. Engineering (Beijing) 2021. [PMID: 34815890 DOI: 10.1016/j.eng.2021.09.007] [Reference Citation Analysis]
37 Tomerak S, Khan S, Almasri M, Hussein R, Abdelati A, Aly A, Salameh MA, Saed Aldien A, Naveed H, Elshazly MB, Zakaria D. Systemic inflammation in COVID‐19 patients may induce various types of venous and arterial thrombosis: A systematic review. Scand J Immunol 2021;94. [DOI: 10.1111/sji.13097] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Hafezi B, Chan L, Knapp JP, Karimi N, Alizadeh K, Mehrani Y, Bridle BW, Karimi K. Cytokine Storm Syndrome in SARS-CoV-2 Infections: A Functional Role of Mast Cells. Cells 2021;10:1761. [PMID: 34359931 DOI: 10.3390/cells10071761] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Sibilio P, Bini S, Fiscon G, Sponziello M, Conte F, Pecce V, Durante C, Paci P, Falcone R, Norata GD, Farina L, Verrienti A. In silico drug repurposing in COVID-19: A network-based analysis. Biomed Pharmacother 2021;142:111954. [PMID: 34358753 DOI: 10.1016/j.biopha.2021.111954] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Sarfraz A, Sarfraz Z, Sarfraz M, Aftab H, Pervaiz Z. Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies. Turk J Med Sci 2021;51:890-7. [PMID: 33244947 DOI: 10.3906/sag-2010-131] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
41 Kanimozhi G, Pradhapsingh B, Singh Pawar C, Khan HA, Alrokayan SH, Prasad NR. SARS-CoV-2: Pathogenesis, Molecular Targets and Experimental Models. Front Pharmacol 2021;12:638334. [PMID: 33967772 DOI: 10.3389/fphar.2021.638334] [Reference Citation Analysis]
42 Takeda Y, Tamura K, Jamsransuren D, Matsuda S, Ogawa H. Severe Acute Respiratory Syndrome Coronavirus-2 Inactivation Activity of the Polyphenol-Rich Tea Leaf Extract with Concentrated Theaflavins and Other Virucidal Catechins. Molecules 2021;26:4803. [PMID: 34443390 DOI: 10.3390/molecules26164803] [Reference Citation Analysis]
43 Toapanta N, Torres IB, Sellarés J, Chamoun B, Serón D, Moreso F. Kidney transplantation and COVID-19 renal and patient prognosis. Clin Kidney J 2021;14:i21-9. [PMID: 33815780 DOI: 10.1093/ckj/sfab030] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
44 Goßlau Y, Warm TD, Hernandez Cancino EF, Braun G, Spring O, Zerwes S, Hyhlik-Dürr A. [Deep Vein Thrombosis in Intensive Care Patients with COVID-19 Infection - Impact of a Standardised Therapeutic Regimen]. Zentralbl Chir 2021;146:605-11. [PMID: 34706375 DOI: 10.1055/a-1630-8163] [Reference Citation Analysis]
45 Cavalli G, Farina N, Campochiaro C, De Luca G, Della-Torre E, Tomelleri A, Dagna L. Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic. Front Pharmacol 2020;11:598308. [PMID: 33442386 DOI: 10.3389/fphar.2020.598308] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
46 Karatas M, Tatar E, Simsek C, Yıldırım AM, Ari A, Zengel B, Uslu A. COVID-19 pneumonia in kidney transplant recipients: A promising treatment algorithm in the absence of a disease-specific drug. J Med Virol 2021;93:5789-97. [PMID: 34050953 DOI: 10.1002/jmv.27110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
47 Whyte MB, Vas PRJ, Umpleby AM. Could Exogenous Insulin Ameliorate the Metabolic Dysfunction Induced by Glucocorticoids and COVID-19? Front Endocrinol (Lausanne) 2021;12:649405. [PMID: 34220705 DOI: 10.3389/fendo.2021.649405] [Reference Citation Analysis]
48 Martell EM, González-Garcia M, Ständker L, Otero-González AJ. Host defense peptides as immunomodulators: The other side of the coin. Peptides 2021;146:170644. [PMID: 34464592 DOI: 10.1016/j.peptides.2021.170644] [Reference Citation Analysis]
49 Quartuccio L, Fabris M, Sonaglia A, Peghin M, Domenis R, Cifù A, Curcio F, Tascini C. Interleukin 6, soluble interleukin 2 receptor alpha (CD25), monocyte colony-stimulating factor, and hepatocyte growth factor linked with systemic hyperinflammation, innate immunity hyperactivation, and organ damage in COVID-19 pneumonia. Cytokine 2021;140:155438. [PMID: 33493861 DOI: 10.1016/j.cyto.2021.155438] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
50 Mangkuliguna G, Glenardi, Susanto N, Pramono LA. Efficacy and Safety of Azithromycin for the Treatment of COVID-19: A Systematic Review and Meta-analysis. Tuberc Respir Dis (Seoul) 2021. [PMID: 34015868 DOI: 10.4046/trd.2021.0075] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
51 El Ouali S, Rubin DT, Cohen BL, Regueiro MD, Rieder F. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol 2021;37:313-9. [PMID: 33859104 DOI: 10.1097/MOG.0000000000000741] [Reference Citation Analysis]
52 Favalli EG, Maioli G, Biggioggero M, Caporali R. Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. Expert Rev Clin Immunol 2021;17:561-71. [PMID: 33787418 DOI: 10.1080/1744666X.2021.1908887] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Croci S, Bonacini M, Dolci G, Massari M, Facciolongo N, Pignatti E, Pisciotta A, Carnevale G, Negro A, Cassone G, Muratore F, Belloni L, Zerbini A, Salvarani C. Human Dental Pulp Stem Cells Modulate Cytokine Production in vitro by Peripheral Blood Mononuclear Cells From Coronavirus Disease 2019 Patients. Front Cell Dev Biol 2020;8:609204. [PMID: 33634100 DOI: 10.3389/fcell.2020.609204] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Van den Eynde E, Gasch O, Oliva JC, Prieto E, Calzado S, Gomila A, Machado ML, Falgueras L, Ortonobes S, Morón A, Capilla S, Navarro G, Oristrell J, Cervantes M, Navarro M. Corticosteroids and tocilizumab reduce in-hospital mortality in severe COVID-19 pneumonia: a retrospective study in a Spanish hospital. Infect Dis (Lond) 2021;53:291-302. [PMID: 33620019 DOI: 10.1080/23744235.2021.1884286] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
55 Hamed AA, Fandy TE, Tkaczuk KL, Verspoor K, Lee BS. COVID-19 Drug Repurposing: A Network-Based Framework for Exploring Biomedical Literature and Clinical Trials for Possible Treatments. Pharmaceutics 2022;14:567. [DOI: 10.3390/pharmaceutics14030567] [Reference Citation Analysis]
56 Kröker A, Tirzīte M. Repurposed pharmacological agents for the potential treatment of COVID-19: a literature review. Respir Res 2021;22:304. [PMID: 34838020 DOI: 10.1186/s12931-021-01885-8] [Reference Citation Analysis]
57 Lavie CJ. In Reply-Use of Famotidine and Risk of Severe Course of Illness in Patients With COVID-19: A Meta-analysis. Mayo Clin Proc 2021;96:1367-8. [PMID: 33958066 DOI: 10.1016/j.mayocp.2021.03.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Zarkesh K, Entezar-Almahdi E, Ghasemiyeh P, Akbarian M, Bahmani M, Roudaki S, Fazlinejad R, Mohammadi-Samani S, Firouzabadi N, Hosseini M, Farjadian F. Drug-based therapeutic strategies for COVID-19-infected patients and their challenges. Future Microbiol 2021;16:1415-51. [PMID: 34812049 DOI: 10.2217/fmb-2021-0116] [Reference Citation Analysis]
59 Pascual-Figal DA, Roura-Piloto AE, Moral-Escudero E, Bernal E, Albendín-Iglesias H, Pérez-Martínez MT, Noguera-Velasco JA, Cebreiros-López I, Hernández-Vicente Á, Vázquez-Andrés D, Sánchez-Pérez C, Khan A, Sánchez-Cabo F, García-Vázquez E; COL-COVID Investigators. Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID). Int J Gen Med 2021;14:5517-26. [PMID: 34539185 DOI: 10.2147/IJGM.S329810] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
60 Schindell BG, Allardice M, Lockman S, Kindrachuk J. Integrating Proteomics for Facilitating Drug Identification and Repurposing During an Emerging Virus Pandemic. ACS Infect Dis 2021;7:1303-16. [PMID: 33319978 DOI: 10.1021/acsinfecdis.0c00579] [Reference Citation Analysis]
61 Chen L, Yang Y, Fan J, Zhang Y, Li N. Trends of High-Impact Studies in Pharmacology and Pharmacy: A Cross-Sectional Study. Front Pharmacol 2021;12:726668. [PMID: 34603039 DOI: 10.3389/fphar.2021.726668] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Ruetsch C, Brglez V, Crémoni M, Zorzi K, Fernandez C, Boyer-Suavet S, Benzaken S, Demonchy E, Risso K, Courjon J, Cua E, Ichai C, Dellamonica J, Passeron T, Seitz-Polski B. Functional Exhaustion of Type I and II Interferons Production in Severe COVID-19 Patients. Front Med (Lausanne) 2020;7:603961. [PMID: 33585507 DOI: 10.3389/fmed.2020.603961] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
63 Pennisi M, Lanza G, Falzone L, Fisicaro F, Ferri R, Bella R. SARS-CoV-2 and the Nervous System: From Clinical Features to Molecular Mechanisms. Int J Mol Sci 2020;21:E5475. [PMID: 32751841 DOI: 10.3390/ijms21155475] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 23.0] [Reference Citation Analysis]
64 Morgulchik N, Athanasopoulou F, Chu E, Lam Y, Kamaly N. Potential therapeutic approaches for targeted inhibition of inflammatory cytokines following COVID-19 infection-induced cytokine storm. Interface Focus 2022;12:20210006. [PMID: 34956607 DOI: 10.1098/rsfs.2021.0006] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Kuznik B, Khavinson V, Shapovalov K, Linkova N, Lukyanov S, Smolyakov Y, Tereshkov P, Shapovalov Y, Konnov V, Tsybikov N. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients. Adv Gerontol 2021;11:368-76. [DOI: 10.1134/s2079057021040068] [Reference Citation Analysis]
66 Karmakar D, Lahiri B, Ranjan P, Chatterjee J, Lahiri P, Sengupta S. Road Map to Understanding SARS-CoV-2 Clinico-Immunopathology and COVID-19 Disease Severity. Pathogens 2020;10:5. [PMID: 33374748 DOI: 10.3390/pathogens10010005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
67 Oldenburg CE, Doan T. Azithromycin for severe COVID-19. Lancet 2020;396:936-7. [PMID: 32896293 DOI: 10.1016/S0140-6736(20)31863-8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 12] [Article Influence: 13.0] [Reference Citation Analysis]
68 Miners S, Kehoe PG, Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther 2020;12:170. [PMID: 33380345 DOI: 10.1186/s13195-020-00744-w] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 10.5] [Reference Citation Analysis]
69 Vijenthira A, Gong IY, Fox TA, Booth S, Cook G, Fattizzo B, Martín-Moro F, Razanamahery J, Riches JC, Zwicker J, Patell R, Vekemans MC, Scarfò L, Chatzikonstantinou T, Yildiz H, Lattenist R, Mantzaris I, Wood WA, Hicks LK. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood 2020;136:2881-92. [PMID: 33113551 DOI: 10.1182/blood.2020008824] [Cited by in Crossref: 65] [Cited by in F6Publishing: 79] [Article Influence: 65.0] [Reference Citation Analysis]
70 Jarai BM, Stillman Z, Bomb K, Kloxin AM, Fromen CA. Biomaterials-Based Opportunities to Engineer the Pulmonary Host Immune Response in COVID-19. ACS Biomater Sci Eng 2021;7:1742-64. [PMID: 33356134 DOI: 10.1021/acsbiomaterials.0c01287] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
71 Carbone M, Lednicky J, Xiao SY, Venditti M, Bucci E. Coronavirus 2019 Infectious Disease Epidemic: Where We Are, What Can Be Done and Hope For. J Thorac Oncol 2021;16:546-71. [PMID: 33422679 DOI: 10.1016/j.jtho.2020.12.014] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
72 Pennisi M, Lanza G, Falzone L, Fisicaro F, Ferri R, Bella R. SARS-CoV-2 and the Nervous System: From Clinical Features to Molecular Mechanisms. Int J Mol Sci 2020;21:E5475. [PMID: 32751841 DOI: 10.3390/ijms21155475] [Reference Citation Analysis]
73 Peng X, Wang Y, Xi X, Jia Y, Tian J, Yu B, Tian J. Promising Therapy for Heart Failure in Patients with Severe COVID-19: Calming the Cytokine Storm. Cardiovasc Drugs Ther 2021;35:231-47. [PMID: 33404925 DOI: 10.1007/s10557-020-07120-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
74 Khosravi M. Candidate Psychotropics against SARS - CoV - 2: A Narrative Review. Pharmacopsychiatry 2021. [PMID: 34399430 DOI: 10.1055/a-1551-3756] [Reference Citation Analysis]
75 Zhang H, Tang Y, Tao J. Sex-Related Overactivation of NLRP3 Inflammasome Increases Lethality of the Male COVID-19 Patients. Front Mol Biosci 2021;8:671363. [PMID: 34150848 DOI: 10.3389/fmolb.2021.671363] [Reference Citation Analysis]
76 Singh PK, Lalwani LK, Govindagoudar MB, Aggarwal R, Chaudhry D, Kumar P, Gehlaut P. Tofacitinib Associated with Reduced Intubation Rates in the Management of Severe COVID-19 Pneumonia: A Preliminary Experience. Indian J Crit Care Med 2021;25:1108-12. [PMID: 34916741 DOI: 10.5005/jp-journals-10071-23964] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
77 Ali FEM, Mohammedsaleh ZM, Ali MM, Ghogar OM. Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. World J Gastroenterol 2021; 27(15): 1531-1552 [PMID: 33958841 DOI: 10.3748/wjg.v27.i15.1531] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
78 Hou X, Tian L, Zhou L, Jia X, Kong L, Xue Y, Hao H, Meng X, Zhang F, Dong X. Intravenous immunoglobulin-based adjuvant therapy for severe COVID-19: a single-center retrospective cohort study. Virol J 2021;18:101. [PMID: 34020680 DOI: 10.1186/s12985-021-01575-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
79 Hage R, Steinack C, Gautschi F, Schuurmans MM. Transplant Drugs against SARS, MERS and COVID-19. Transplantology 2020;1:71-84. [DOI: 10.3390/transplantology1020007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
80 Rizk JG, Forthal DN, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Pfeiffer JP, Lewin JC. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. Drug Discov Today 2021;26:593-603. [PMID: 33253920 DOI: 10.1016/j.drudis.2020.11.025] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 7.5] [Reference Citation Analysis]
81 Chiang KC, Rizk JG, Nelson DJ, Krishnamurti L, Subbian S, Imig JD, Khan I, Reddy ST, Gupta A. Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert Opinion on Therapeutic Targets. [DOI: 10.1080/14728222.2022.2031975] [Reference Citation Analysis]
82 Rizk JG, Lazo JG Jr, Quan D, Gabardi S, Rizk Y, Streja E, Kovesdy CP, Kalantar-Zadeh K. Mechanisms and management of drug-induced hyperkalemia in kidney transplant patients. Rev Endocr Metab Disord 2021. [PMID: 34292479 DOI: 10.1007/s11154-021-09677-7] [Reference Citation Analysis]
83 Schieffer E, Schieffer B, Hilfiker-Kleiner D. [Cardiovascular diseases and COVID-19 : Pathophysiology, complications and treatment]. Herz 2021;46:107-14. [PMID: 33394058 DOI: 10.1007/s00059-020-05013-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
84 Mormile R. Il-6, Il-1β and cytokine-targeted therapy for COVID -19 patients: two more reasons to take into account statins? Expert Rev Cardiovasc Ther 2022;:1-3. [PMID: 35323082 DOI: 10.1080/14779072.2022.2058490] [Reference Citation Analysis]
85 Nezgovorova V, Ferretti CJ, Pallanti S, Hollander E. Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder. J Psychiatr Res 2021:S0022-3956(21)00674-9. [PMID: 34809994 DOI: 10.1016/j.jpsychires.2021.11.025] [Reference Citation Analysis]
86 Rizk JG, Barr CE, Rizk Y, Lewin JC. The next frontier in vaccine safety and VAERS: Lessons from COVID-19 and ten recommendations for action. Vaccine 2021;39:6017-8. [PMID: 34400020 DOI: 10.1016/j.vaccine.2021.08.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
87 Elemam NM, Maghazachi AA, Hannawi S. COVID-19 infection and rheumatoid arthritis: mutual outburst cytokines and remedies. Curr Med Res Opin 2021;37:929-38. [PMID: 33754931 DOI: 10.1080/03007995.2021.1906637] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Engin AB, Engin ED, Engin A. The effect of environmental pollution on immune evasion checkpoints of SARS-CoV-2. Environ Toxicol Pharmacol 2021;81:103520. [PMID: 33132153 DOI: 10.1016/j.etap.2020.103520] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
89 Darwesh AM, Bassiouni W, Sosnowski DK, Seubert JM. Can N-3 polyunsaturated fatty acids be considered a potential adjuvant therapy for COVID-19-associated cardiovascular complications? Pharmacol Ther 2021;219:107703. [PMID: 33031856 DOI: 10.1016/j.pharmthera.2020.107703] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
90 Jacobs CF, Eldering E, Kater AP. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Adv 2021;5:913-25. [PMID: 33560402 DOI: 10.1182/bloodadvances.2020003768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
91 Peymani P, Dehesh T, Aligolighasemabadi F, Sadeghdoust M, Kotfis K, Ahmadi M, Mehrbod P, Iranpour P, Dastghaib S, Nasimian A, Ravandi A, Kidane B, Ahmed N, Sharma P, Shojaei S, Bagheri Lankarani K, Madej A, Rezaei N, Madrakian T, Los MJ, Labouta HI, Mokarram P, Ghavami S. Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients. Transl Med Commun 2021;6:3. [PMID: 33521322 DOI: 10.1186/s41231-021-00082-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 12.0] [Reference Citation Analysis]
92 Levy E, Delvin E, Marcil V, Spahis S. Can phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy tool of novel coronavirus disease 2019 (COVID-19)? Am J Physiol Endocrinol Metab 2020;319:E689-708. [PMID: 32755302 DOI: 10.1152/ajpendo.00298.2020] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
93 Chathappady House NN, Palissery S, Sebastian H. Corona Viruses: A Review on SARS, MERS and COVID-19. Microbiol Insights 2021;14:11786361211002481. [PMID: 33795938 DOI: 10.1177/11786361211002481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
94 Kamath C, Brenner EJ. The safe use of inflammatory bowel disease therapies during the COVID-19 pandemic. Curr Res Pharmacol Drug Discov 2022;3:100101. [PMID: 35496814 DOI: 10.1016/j.crphar.2022.100101] [Reference Citation Analysis]
95 Lariccia V, Magi S, Serfilippi T, Toujani M, Gratteri S, Amoroso S. Challenges and Opportunities from Targeting Inflammatory Responses to SARS-CoV-2 Infection: A Narrative Review. J Clin Med 2020;9:E4021. [PMID: 33322733 DOI: 10.3390/jcm9124021] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
96 Bignardi E, Brogna C, Capasso C, Brogna B. A fatal case of COVID-19 breakthrough infection due to the delta variant. Clin Case Rep 2022;10:e05232. [PMID: 35035958 DOI: 10.1002/ccr3.5232] [Reference Citation Analysis]
97 Niemeyer BF, Benam KH. Untapping host-targeting cross-protective efficacy of anticoagulants against SARS-CoV-2. Pharmacol Ther 2021;:108027. [PMID: 34718070 DOI: 10.1016/j.pharmthera.2021.108027] [Reference Citation Analysis]
98 Li HP, He X, Zhang L, Li CX, Li SQ, Li QY. Therapeutic Agents Rounding Up the Immunopathology of COVID-19. Ther Clin Risk Manag 2021;17:657-68. [PMID: 34234442 DOI: 10.2147/TCRM.S313003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
99 Tang Z, Xiao Y, Kong N, Liu C, Chen W, Huang X, Xu D, Ouyang J, Feng C, Wang C, Wang J, Zhang H, Tao W. Nano-bio interfaces effect of two-dimensional nanomaterials and their applications in cancer immunotherapy. Acta Pharm Sin B 2021;11:3447-64. [PMID: 34900529 DOI: 10.1016/j.apsb.2021.05.004] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
100 Zhang F, Liu W, Huang J, Chen QL, Wang DD, Zou LW, Zhao YF, Zhang WD, Xu JG, Chen HZ, Ge GB. Inhibition of drug-metabolizing enzymes by Jingyin granules: implications of herb-drug interactions in antiviral therapy. Acta Pharmacol Sin 2021. [PMID: 34183756 DOI: 10.1038/s41401-021-00697-2] [Reference Citation Analysis]
101 Županić S, Perić Šitum M, Majdak M, Karakaš M, Bašić S, Sporiš D. Case series of COVID-19 in patients with myasthenia gravis: a single institution experience. Acta Neurol Belg 2021;121:1039-44. [PMID: 33797054 DOI: 10.1007/s13760-021-01662-w] [Reference Citation Analysis]
102 Bassetti M, Corcione S, Dettori S, Lombardi A, Lupia T, Vena A, De Rosa FG, Gori A, Giacobbe DR. Antiviral treatment selection for SARS-CoV-2 pneumonia. Expert Rev Respir Med 2021;15:985-92. [PMID: 33962524 DOI: 10.1080/17476348.2021.1927719] [Reference Citation Analysis]
103 Alhalabi M, Eddin KA, Ali F, Abbas A. SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis: A case report. Medicine (Baltimore) 2022;101:e28722. [PMID: 35089243 DOI: 10.1097/MD.0000000000028722] [Reference Citation Analysis]
104 Rehman SU, Rehman SU, Yoo HH. COVID-19 challenges and its therapeutics. Biomed Pharmacother 2021;142:112015. [PMID: 34388532 DOI: 10.1016/j.biopha.2021.112015] [Reference Citation Analysis]
105 Gülhan M, Önal U, Demirci N, Cetin G, Calisir A, Köksalan D, Solmaz K, Kars A, Kilinc C, Gülten S. Tocilizumab is useful for coronavirus disease 2019 patients: the key point is timing. Rev Assoc Med Bras (1992) 2022;68:318-22. [PMID: 35442357 DOI: 10.1590/1806-9282.20210602] [Reference Citation Analysis]
106 de Cáceres C, Martínez R, Bachiller P, Marín L, García JM. The effect of tocilizumab on cytokine release syndrome in COVID-19 patients. Pharmacol Rep 2020;72:1529-37. [PMID: 33165762 DOI: 10.1007/s43440-020-00186-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]